Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3Withdrawn 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Arthritis, Rheumatoid 4Crohn Disease 3Lymphoma, Follicular 1Adenocarcinoma of Lung 1

Interventions

Infliximab 3Certolizumab Pegol 3golimumab 1Vaccines 1Sutures 1Surgical Instruments 1Soybean Oil 1Saline Solution 1Ringer's Lactate 1Pneumococcal Vaccines 1Photoplethysmography 1Papillomavirus Vaccines 1Methoxsalen 1MEDI2070 1Lysine Acetyltransferase 5 1Laparoscopy 1Hydroxyethyl Starch Derivatives 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Herpes Zoster Vaccine 1Fish Oils 1Calcium Dobesilate 1Calcitriol 1CT-P13 1Bupivacaine 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Crohn Disease × Certolizumab Pegol × Clear all
NCT00552058 2018-08-09

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

UCB Pharma

Phase 3 Completed
439 enrolled 25 charts

Crohn Disease

NCT00333788 2018-08-07

Welcome2

UCB Pharma

Phase 3 Completed
233 enrolled 31 charts

Crohn Disease

NCT00297648 2011-08-31

MUSIC

UCB Pharma

Phase 3 Completed
89 enrolled 43 charts

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡